Regulation, suspicion slow U.S. flu response: hearing

WASHINGTON-Vaccine makers praised the U.S. response to the swine flu pandemic on Wednesday but said regulatory delays and public suspicion have held up innovative ways to speed and stretch the U.S. influenza vaccine supply.
Pharmaceutical executives said their companies were working on ways to make flu vaccines more quickly and in greater quantities, but said regulatory approval was slow. They complained about U.S. reluctance to use additives called adjuvants that can boost a vaccine's effects...

READ MORE